What do systematic reviews say?

Anti‐CD20 mAb maintenance therapy vs observation

Anti‐CD20 mAb maintenance therapy showed no clear difference in overall survival compared with observation (moderate certainty).

• Maintenance therapy for chronic lymphocytic leukaemia 2024 · Cochrane Headline outcomes only
  HR 0.94 [0.73, 1.2]
  3 studies · 1152 participants
  Moderate

Immunomodulatory drug maintenance therapy vs placebo/observation

Immunomodulatory drug maintenance therapy showed no clear difference in overall survival compared with placebo/observation (moderate certainty).

• Maintenance therapy for chronic lymphocytic leukaemia 2024 · Cochrane Headline outcomes only
  HR 0.91 [0.61, 1.35]
  3 studies · 461 participants
  Moderate

Intervention not reported

The intervention probably leads to higher overall survival (moderate certainty).

• Interim PET‐results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta‐analysis of prognostic… 2020 · Cochrane Headline outcomes only
  HR 5.09 [2.64, 9.81]
  9 studies · 1802 participants
  Moderate

Thrombopoietin mimetics vs placebo

• Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 282 participants
  GRADE not reported

G‐CSF vs placebo

It is very uncertain whether G‐CSF changes overall survival compared with placebo (very low certainty).

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  HR 0.8 [0.44, 1.46]
  1 study · 64 participants
  Very low

Intervention not reported

The review found no eligible studies for this question.

• The role of iron in the management of chemotherapy‐induced anemia in cancer patients receiving… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Bortezomib vs no bortezomib

Bortezomib leads to lower overall Survival compared with no bortezomib (high certainty).

• Bortezomib for the treatment of multiple myeloma 2016 · Cochrane Headline outcomes only
  Odds Ratio 0.77 [0.69, 0.86]
  9 studies · 4118 participants
  High

Intervention not reported

The review found no eligible studies for this question.

• Meditation for adults with haematological malignancies 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Low molecular weight heparin vs placebo or no treatment

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Glutamine vs placebo

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Fresh frozen plasma vs no treatment

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Antithrombin III plus heparin vs heparin

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Heparin vs low molecular weight heparin

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Heparin vs prostaglandin E1

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Low molecular weight heparin vs prostaglandin E1

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Positron emission tomography‐adapted therapy for first‐line treatment in individuals with Hodgkin lymphoma 2015 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1480 participants
  Very low

Mycophenolate mofetil vs methotrexate

Mycophenolate mofetil showed no clear difference in overall survival compared with methotrexate (low certainty).

• Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease in people receiving allogeneic… 2014 · Cochrane Headline outcomes only
  HR 0.73 [0.45, 1.17]
  2 studies · 129 participants
  Low

Intervention not reported

The intervention showed no clear difference in overall survival (high certainty).

• Erythropoietin or darbepoetin for patients with cancer 2012 · Cochrane Headline outcomes only
  HR 1.05 [1, 1.11]
  78 studies · 19003 participants
  High

Intervention not reported

The intervention showed no clear difference in overall survival (moderate certainty).

• High‐dose therapy with autologous stem cell transplantation versus chemotherapy or immuno‐chemotherapy for follicular… 2012 · Cochrane Headline outcomes only
  HR 0.97 [0.76, 1.22]
  3 studies · 701 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in overall survival (low certainty).

• Colony‐stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous… 2012 · Cochrane Headline outcomes only
  HR 1 [0.93, 1.08]
  11 studies · 3335 participants
  Low